Identification

Name
Doxorubicin
Accession Number
DB00997  (APRD00185, DB05331, DB05847)
Type
Small Molecule
Groups
Approved, Investigational
Description

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.

Structure
Thumb
Synonyms
  • (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
  • (8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • 14-hydroxydaunomycin
  • 14-hydroxydaunorubicine
  • Doxorubicin
  • Doxorubicina
  • Doxorubicine
  • Doxorubicinum
  • Hydroxydaunorubicin
Product Ingredients
IngredientUNIICASInChI Key
Doxorubicin citrateAJQ2ZNG2WL111266-55-8INEKNBHAPBIAFK-RUELKSSGSA-N
Doxorubicin hydrochloride82F2G7BL4E25316-40-9MWWSFMDVAYGXBV-RUELKSSGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adriamycin PFSSolutionIntravenous; IntravesicalPfizer Canada Ulc1995-12-31Not applicableCanada
Adriamycin RdfPowder, for solutionIntravenousPfizer Canada Ulc1996-12-312006-08-02Canada
Adriamycin RdfPowder, for solutionIntravenousPfizer Canada Ulc1996-12-312006-08-02Canada
Adriamycin RdfPowder, for solutionIntravenousPfizer Canada Ulc1995-12-312006-08-02Canada
Adriamycin Rdf Inj 10mg/vialPowder, for solutionIntravenousCarlo Erba Farmitalia Spa1976-12-311996-09-10Canada
Adriamycin Rdf Inj 150mg/vialPowder, for solutionIntravenousAdria Laboratories Of Canada Ltd.1988-12-311996-09-10Canada
Adriamycin Rdf Inj 50mg/vialPowder, for solutionIntravenousCarlo Erba Farmitalia Spa1976-12-311996-09-10Canada
CaelyxSuspensionIntravenousJanssen Pharmaceuticals1998-08-19Not applicableCanada
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdriamycinInjection, solution2 mg/1mLIntravenousHikma Pharmaceuticals USA Inc.1996-05-01Not applicableUs
AdriamycinInjection, powder, lyophilized, for solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
AdriamycinInjection, powder, lyophilized, for solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
AdriamycinInjection, solution2 mg/1mLIntravenousHikma Pharmaceuticals USA Inc.1996-05-01Not applicableUs
AdriamycinInjection, solution2 mg/1mLIntravenousHikma Pharmaceuticals USA Inc.1996-05-01Not applicableUs
AdriamycinInjection, powder, lyophilized, for solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
AdriamycinInjection, solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
AdriamycinInjection, solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
AdriamycinInjection, solution2 mg/1mLIntravenousHikma Pharmaceuticals USA Inc.1996-05-01Not applicableUs
AdriamycinInjection, solution2 mg/1mLIntravenousBedford Pharmaceuticals1996-05-012014-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Doxorubicin HydrochlorideDoxorubicin hydrochloride (2 mg/1mL)Injection, powder, lyophilized, for solutionIntra-arterial; Intravenous; IntravesicalHospira, Inc.2016-04-182017-12-31Us
LipodoxDoxorubicin hydrochloride (2 mg/1mL)Injectable, liposomalIntravenousSun Pharma Global FZE2012-02-09Not applicableUs
Lipodox 50Doxorubicin hydrochloride (2 mg/1mL)Injectable, liposomalIntravenousSun Pharma Global FZE2012-02-09Not applicableUs
International/Other Brands
Adriablastina (Pfizer) / Adriblastin (Actavis)
Categories
UNII
80168379AG
CAS number
23214-92-8
Weight
Average: 543.5193
Monoisotopic: 543.174060775
Chemical Formula
C27H29NO11
InChI Key
AOJJSUZBOXZQNB-TZSSRYMLSA-N
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O

Pharmacology

Indication

Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

Associated Conditions
Pharmacodynamics

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Mechanism of action

Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

TargetActionsOrganism
ADNA
intercalation
Humans
ADNA topoisomerase 2-alpha
inhibitor
Humans
UNucleolar and coiled-body phosphoprotein 1Not AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution

The distributive half-life is 5 minutes, which suggests that doxorubicin is rapidly taken up by tissue. Steady state volume of distribution = 809 to 1214 L/m2

Protein binding

Doxorubicin and its major metabolite, doxorubicinol, is 74-76% bound to plasma protein. The extent to binding is independent of plasma concentration up to 1.1 mcg/mL. Doxorubicin does not cross the blood brain barrier.

Metabolism

Doxorubicin is capable of undergoing 3 metabolic routes: one-electron reduction, two-electron reduction, and deglycosidation. However, approximately half of the dose is eliminated from the body unchanged. Two electron reduction yields doxorubicinol, a secondary alcohol. This pathway is considered the primary metabolic pathway. The one electron reduction is facilitated by several oxidoreductases to form a doxirubicin-semiquinone radical. These enzymes include mitochondrial and cystolic NADPH dehydrogenates, xanthine oxidase, and nitric oxide synthases. Deglycosidation is a minor metabolic pathway (1-2% of the dose undergoes this pathway). The resultant metabolites are deoxyaglycone or hydroxyaglycone formed via reduction or hydrolysis respectively. Enzymes that may be involved with this pathway include xanthine oxidase, NADPH-cytochrome P450 reductase, and cytosolic NADPH dehydrogenase.

Route of elimination

40% of the dose appears in bile in 5 days. 5-12% of the drug and its metabolites appears in urine during the same time period. <3% of the dose recovered in urine was doxorubicinol.

Half life

Terminal half life = 20 - 48 hours.

Clearance
  • 324-809 mL/min/m2 [by metabolism and biliary excretion]
  • 1088 mL/min/m2 [Men]
  • 433 mL/min/m2 [Women]
  • 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses]
  • 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]
Toxicity

LD50=21800 ug/kg (rat, subcutaneous)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Doxorubicin Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Retinoic acid receptor gamma---(C;C) / (C;T)C>TADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.Details
Solute carrier family 28 member 3---(A;A) / (A;G)G > AADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.Details
UDP-glucuronosyltransferase 1-6UGT1A6*4(T;T) / (G;T)G > TADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Doxorubicin.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Doxorubicin.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Doxorubicin is combined with 2-Methoxyethanol.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Doxorubicin.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Doxorubicin.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Doxorubicin.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Doxorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be decreased when combined with Doxorubicin.
AbataceptThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Abatacept.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Doxorubicin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Drink plenty of fluids. Increased fluid intake increases urine output and the excretion of uric acid.

References

Synthesis Reference

Gian P. Vicario, Sergio Penco, Federico Arcamone, "Daunorubicin and doxorubicin labelled with .sup.14 C at the 14-position and processes for their preparation." U.S. Patent US4211864, issued March, 1976.

US4211864
General References
  1. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992 Dec;19(6):670-86. [PubMed:1462166]
  2. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333-53. [PubMed:4290058]
  3. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969 Nov;11(6):1101-10. [PubMed:5365804]
  4. Di Marco A, Gaetani M, Scarpinato B: Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969 Feb;53(1):33-7. [PubMed:5772652]
  5. Lomovskaya N, Otten SL, Doi-Katayama Y, Fonstein L, Liu XC, Takatsu T, Inventi-Solari A, Filippini S, Torti F, Colombo AL, Hutchinson CR: Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene. J Bacteriol. 1999 Jan;181(1):305-18. [PubMed:9864344]
  6. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B: New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16(13):1656-72. [PubMed:19442138]
  7. Minotti G: Reactions of adriamycin with microsomal iron and lipids. Free Radic Res Commun. 1989;7(3-6):143-8. [PubMed:2555273]
External Links
Human Metabolome Database
HMDB0015132
KEGG Drug
D03899
KEGG Compound
C01661
PubChem Compound
31703
PubChem Substance
46507641
ChemSpider
29400
BindingDB
32022
RxNav
3639
ChEBI
28748
ChEMBL
CHEMBL53463
ZINC
ZINC000003918087
Therapeutic Targets Database
DNC000163
PharmGKB
PA449412
PDBe Ligand
DM2
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxorubicin
ATC Codes
L01DB01 — Doxorubicin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
151d / 1d12 / 1da9 / 1i1e / 1p20 / 2dr6 / 4dx7 / 4zvm / 5mra / 5om7
show 2 more
FDA label
Download (105 KB)
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentBreast Cancer / Pregnancy1
0CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
0CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
0CompletedTreatmentOvarian Cancer / Sarcomas1
0Not Yet RecruitingOtherMetastatic Sarcoma / Recurrent Sarcoma / Resectable Sarcoma1
0Not Yet RecruitingTreatmentLymphoma Leukemia1
0RecruitingTreatmentAnn Arbor Stage I Diffuse Large B-Cell Lymphoma / Ann Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / Plasmablastic Lymphoma1
0RecruitingTreatmentMalignant Abdominal Neoplasm / Malignant Pelvic Neoplasm / Recurrent Colon Carcinoma / Recurrent Desmoplastic Small Round Cell Tumor / Recurrent Fallopian Tube Carcinoma / Recurrent Gastric Carcinoma / Recurrent Liposarcoma / Recurrent Malignant Mesothelioma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Rectal Carcinoma / Recurrent Rhabdomyosarcoma / Recurrent Sarcoma / Refractory Colon Carcinoma / Refractory Desmoplastic Small Round Cell Tumor / Refractory Fallopian Tube Carcinoma / Refractory Gastric Carcinoma / Refractory Liposarcoma / Refractory Malignant Mesothelioma / Refractory Ovarian Carcinoma / Refractory Primary Peritoneal Carcinoma / Refractory Rectal Carcinoma / Refractory Rhabdomyosarcoma / Refractory Sarcoma / Resectable Liposarcoma / Resectable Malignant Mesothelioma / Resectable Sarcoma1
0RecruitingTreatmentNK-Cell Leukemia / NK-Cell Lymphoma / Peripheral T Cell Lymphoma (PTCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAdvanced Solid Tumors Amenable to Anthracycline Therapy / Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy1
1Active Not RecruitingTreatmentAnn Arbor Stage III Non-Hodgkin Lymphoma / Ann Arbor Stage IV Non-Hodgkin Lymphoma / Solid Neoplasms / Stage III Non-Hodgkin Lymphoma / Stage IV Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentBreast Cancer1
1Active Not RecruitingTreatmentCutaneous Lymphomas / Malignant Lymphomas / T-cell type lymphoma1
1Active Not RecruitingTreatmentHigh Grade B-cell Lymphoma / High-grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentMetastatic Angiosarcoma / Metastatic Epithelioid Sarcoma / Metastatic Fibrosarcoma / Metastatic Leiomyosarcoma / Metastatic Liposarcoma / Metastatic Malignant Peripheral Nerve Sheath Tumor / Metastatic Synovial Sarcoma / Metastatic Undifferentiated Pleomorphic Sarcoma / Myxofibrosarcoma / Pleomorphic Rhabdomyosarcoma / Stage III Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma / Undifferentiated (Embryonal) Sarcoma1
1Active Not RecruitingTreatmentOvarian Cancer1
1Active Not RecruitingTreatmentSarcomas1
1Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1Active Not RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentTumors, Solid / Urethral Cancer1
1CompletedBasic ScienceMalignant Lymphomas1
1CompletedBasic ScienceSoft Tissue Sarcoma (STS)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1CompletedTreatmentAdrenocortical Carcinoma / Breast Cancer / Colorectal Cancers / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone / Childhood Angiosarcoma / Childhood Desmoplastic Small Round Cell Tumor / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Malignant Peripheral Nerve Sheath Tumor / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Malignant Adult Hemangiopericytoma / Malignant Childhood Hemangiopericytoma / Metastatic Childhood Soft Tissue Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumours1
1CompletedTreatmentAdvanced or Refractory Solid Malignancies / Neoplasms / Neoplasms, Breast / Neoplasms, Ovarian1
1CompletedTreatmentBone Cancer / Childhood Liver Cancer / Childhood Soft Tissue Sarcoma / Kidney Tumors / Neoplasms, Brain1
1CompletedTreatmentBreast Cancer7
1CompletedTreatmentBreast Cancer / Chronic Myeloproliferative Disorders / Colorectal Cancers / Head and Neck Carcinoma / Leukemias / Lung Cancers / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic/Myeloproliferative Diseases / Prostate Cancer / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer / Gastrointestinal Cancers / Genitourinary Cancers / Gynecologic Cancers / Sarcomas1
1CompletedTreatmentCancer, Advanced4
1CompletedTreatmentCancer, Bladder / Transitional Cell Cancer of the Renal Pelvis and Ureter2
1CompletedTreatmentCarcinoma NOS / Fallopian Tube Cancer / Gynecological Malignancies / Malignancies / Metastases / Oncology / Ovarian Cancer / Tumors / Tumors, Solid1
1CompletedTreatmentCarcinoma NOS / Malignancies1
1CompletedTreatmentCardiac Toxicity / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChildhood Solid Neoplasm / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentComposite Lymphoma / Grade 3b Follicular Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Follicular Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Follicular Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Follicular Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Follicular Lymphoma1
1CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Adenocarcinomas / Neuroendocrine Tumors / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)1
1CompletedTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Cancer / Fallopian Tube Cancer / Ovarian Cancer / Tumors, Solid1
1CompletedTreatmentEpithelial Ovarian Carcinoma / Fallopian Tube Cancer / Neoplasms, Ovarian / Primary Peritoneal Carcinoma1
1CompletedTreatmentEsophageal Cancers / Head and Neck Carcinoma / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Cell Lung Cancer (SCLC)1
1CompletedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Triple-Negative Breast Carcinoma1
1CompletedTreatmentEwing's Sarcoma (ES) / Neuroectodermal Tumors, Primitive / Neuroepithelioma / Sarcoma, Osteogenic / Sarcomas1
1CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer2
1CompletedTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
1CompletedTreatmentGastrointestinal Stromal Tumors / Recurrent Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1CompletedTreatmentGlioblastomas1
1CompletedTreatmentHER2 Positive Breast Cancers / Her2-negative Metastatic Breast Cancer / HER2-positive Metastatic Breast Cancer / Locally Advanced or Early Breast Cancer1
1CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer / Localized Unresectable Liver Cancer1
1CompletedTreatmentHepatocellular,Carcinoma / Neoplasms1
1CompletedTreatmentHepatocellular,Carcinoma / Neoplasms, Hepatic1
1CompletedTreatmentHodgkins Disease (HD)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentLiver Cancer1
1CompletedTreatmentLiver Cancer / Metastatic Cancers1
1CompletedTreatmentLung Cancers / Mesothelioma, Malignant / Metastatic Cancers1
1CompletedTreatmentLung Cancers / Metastatic Cancers1
1CompletedTreatmentLymphoma, Hodgkins1
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-cell type lymphoma1
1CompletedTreatmentMalignancies2
1CompletedTreatmentMalignancies / Sarcomas1
1CompletedTreatmentMalignant Gliomas1
1CompletedTreatmentMalignant Lymphomas3
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms Metastasis1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Hepatic1
1CompletedTreatmentNeoplasms, Ovarian1
1CompletedTreatmentNeoplasms / Neoplasms by Histologic Type / Neoplasms, Connective and Soft Tissue / Sarcomas / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentNeuroblastomas2
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentOvarian Cancer2
1CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Ovarian Undifferentiated Carcinoma / Recurrent Fallopian Tube Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Carcinoma / Recurrent Primary Peritoneal Cavity Cancer / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentProstate Cancer2
1CompletedTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Ovarian Cancer1
1CompletedTreatmentRecurrent Ovarian Epithelial Cancer1
1CompletedTreatmentRecurrent Small Cell Lung Carcinoma1
1CompletedTreatmentResistant Solid Malignancies1
1CompletedTreatmentSarcomas5
1CompletedTreatmentSarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentSoft Tissue Sarcoma (STS)3
1CompletedTreatmentTriple Negative Breast Neoplasms1
1CompletedTreatmentTumors, Solid3
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific5
1Not Yet RecruitingOtherGastric Adenocarcinoma / Malignant Neoplasm of Stomach1
1Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / ALK-Positive Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Primary Mediastinal (Thymic) Large B-cell Lymphoma / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / All / ALL, Childhood1
1Not Yet RecruitingTreatmentAcute Adult T-Cell Leukemia/Lymphoma / Adult T-Cell Leukemia/Lymphoma / Chronic Adult T-Cell Leukemia/Lymphoma / HTLV-1 Infection1
1Not Yet RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage II Follicular Lymphoma / Ann Arbor Stage II Marginal Zone Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Follicular Lymphoma / Ann Arbor Stage III Marginal Zone Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Follicular Lymphoma / Ann Arbor Stage IV Marginal Zone Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Not Yet RecruitingTreatmentBasal Cell Carcinoma (BCC)1
1Not Yet RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Fallopian Tube Undifferentiated Carcinoma / FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma / FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma / FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma / High Grade Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Undifferentiated Carcinoma / Platinum-Sensitive Ovarian Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma / Primary Peritoneal Transitional Cell Carcinoma / Primary Peritoneal Undifferentiated Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma / Recurrent Low Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Clear Cell Adenocarcinoma / Recurrent Ovarian Endometrioid Adenocarcinoma / Recurrent Ovarian Mucinous Adenocarcinoma / Recurrent Ovarian Transitional Cell Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma1
1Not Yet RecruitingTreatmentHematologic Diseases1
1Not Yet RecruitingTreatmentLiver Cancer1
1Not Yet RecruitingTreatmentOvarian Cancer1
1Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1Not Yet RecruitingTreatmentUnrecognized Condition1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentALL, Childhood / Lymphoblastic Leukemia, Acute, Childhood / Lymphoblastic Lymphoma, Childhood1
1RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Refractory Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse1
1RecruitingTreatmentAdenocarcinoma Breast / Breast Cancer / Invasive Ductal Breast Carcinoma / Invasive Ductal Carcinoma of Female Breast / Metastatic Breast Cancer / Metastatic Cancers / Neoplasms, Breast / Stage IV Breast Cancer1
1RecruitingTreatmentAdvanced Cancers / Advanced Malignant Neoplasm / Recurrent Malignant Neoplasm / Refractory Malignant Neoplasm1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Astrocytomas / Glioblastomas / Gliomas / Mixed Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas / Optic Nerve Glioma / Pilocytic Astrocytoma1
1RecruitingTreatmentAnatomic Stage 0 Breast Cancer AJCC v8 / Anatomic Stage I Breast Cancer AJCC v8 / Anatomic Stage IA Breast Cancer AJCC v8 / Anatomic Stage IB Breast Cancer AJCC v8 / Anatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Early-Stage Breast Carcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Prognostic Stage 0 Breast Cancer AJCC v8 / Prognostic Stage I Breast Cancer AJCC v8 / Prognostic Stage IA Breast Cancer AJCC v8 / Prognostic Stage IB Breast Cancer AJCC v8 / Prognostic Stage II Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Negative / CD20 Positive / HIV Positivity / Human Immunodeficiency Virus Positive / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentBlasts 5 Percent or More of Bone Marrow Nucleated Cells / Blasts 5 Percent or More of Peripheral Blood White Cells / CD22 Positive / Recurrent B Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Refractory B Acute Lymphoblastic Leukemia / Refractory B Lymphoblastic Lymphoma1
1RecruitingTreatmentBreast Cancer1
1RecruitingTreatmentBurkitt's Lymphoma / Castleman's Disease, Multicentric / CD20 Positive / HHV8-Positive Multicentric Castleman Disease / Kaposi s Sarcoma (KS) / KSHV-associated Multicentric Castleman Disease / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentCutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma (CTCL)1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Lymphoma, Large B-Cell, Diffuse (DLBCL) / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1RecruitingTreatmentEwing's Sarcoma (ES) / Germ Cell Tumors / Hepatic Tumors / Neuroblastomas / Pediatric Cancer / Rhabdomyosarcomas / Sarcoma, Osteogenic / Soft Tissue Sarcoma (STS) / Tumors, Solid / Wilms' tumor1
1RecruitingTreatmentFIGO Stage IVA Ovarian Cancer / FIGO Stage IVB Ovarian Cancer / Platinum-Resistant Ovarian Carcinoma / Recurrent Fallopian Tube Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Cancer / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Cancer / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Cancer / Recurrent Uterine Corpus Carcinoma / Stage III Fallopian Tube Cancer AJCC v7 / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Primary Peritoneal Cancer AJCC v7 / Stage III Uterine Corpus Cancer AJCC v7 / Stage IIIA Fallopian Tube Cancer / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer AJCC v7 / Stage IV Fallopian Tube Cancer / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer AJCC v7 / Stage IV Primary Peritoneal Cavity Cancer / Stage IV Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer AJCC v71
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentKaposi s Sarcoma (KS)1
1RecruitingTreatmentLeukemia, Acute / Leukemia, Lymphocytic / Leukemia, T-Cell / Lymphoma, Lymphoblastic / Recurrent Disease / T-cell type lymphoma1
1RecruitingTreatmentLiver Cancer1
1RecruitingTreatmentLung Cancer Metastatic / Sarcoma, Bone / Soft Tissue Sarcoma (STS)1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentOvarian Cancer / TNBC - Triple-Negative Breast Cancer1
1RecruitingTreatmentSarcomas1
1TerminatedTreatmentAcute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Cutaneous B-Cell Non-Hodgkin Lymphoma / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentAcute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentBreast Cancer1
1TerminatedTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1TerminatedTreatmentCancer: Solid Tumors1
1TerminatedTreatmentCarcinoma NOS / Neoplasms, Ovarian / Ovarian Cancer / Ovarian Diseases1
1TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer1
1TerminatedTreatmentFallopian Tube Carcinoma / Ovarian Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
1TerminatedTreatmentFallopian Tube Neoplasms / Neoplasms / Neoplasms, Ovarian / Primary Peritoneal Neoplasms1
1TerminatedTreatmentHER2 Positive Breast Cancers / Malignant Neoplasm of Breast1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentOvarian Cancer2
1TerminatedTreatmentStages II-III Breast Cancer1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1Unknown StatusTreatmentMalignancies / Malignant Female Reproductive System Neoplasm / Ovarian Cancer / Ovarian Tumors / Recurrent Ovarian Epithelial Cancer1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1WithdrawnTreatmentBreast Cancer2
1WithdrawnTreatmentBreast Cancer / Cancer of the Breast1
1WithdrawnTreatmentDesmoid / Ewing's Sarcoma (ES) / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic / Sarcomas1
1WithdrawnTreatmentLeiomyosarcomas1
1WithdrawnTreatmentLeukemia, Plasma Cell1
1WithdrawnTreatmentMalignant Lymphomas / Tumors, Solid1
1WithdrawnTreatmentMalignant Neoplasms of Mesothelial and Soft Tissue / Rhabdomyosarcoma, Abdominal / Rhabdomyosarcoma, Pelvic1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Ann Arbor Stage I Diffuse Large B-Cell Lymphoma / Ann Arbor Stage I Grade 3 Follicular Lymphoma / Ann Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma / Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Ann Arbor Stage II Hodgkin Lymphoma / Ann Arbor Stage IIA Hodgkin Lymphoma / Ann Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage III Hodgkin Lymphoma / Ann Arbor Stage IIIA Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / CD30-Positive Neoplastic Cells Present / Classic Hodgkin Lymphoma / Classical Hodgkin's Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma / TNFRSF8 Positive1
1, 2Active Not RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentAnn Arbor Stage II Non-Hodgkin Lymphoma / Ann Arbor Stage III Non-Hodgkin Lymphoma / Ann Arbor Stage IV Non-Hodgkin Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2Active Not RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentBreast Cancer1
1, 2Active Not RecruitingTreatmentCancer, Bladder1
1, 2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1, 2Active Not RecruitingTreatmentEndometrial Cancer / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
1, 2Active Not RecruitingTreatmentHodgkins Disease (HD)1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1, 2Active Not RecruitingTreatmentMalignancies1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)4
1, 2Active Not RecruitingTreatmentOvarian Cancer2
1, 2Active Not RecruitingTreatmentSarcomas1
1, 2CompletedPreventionCancer, Advanced / Tumors, Solid1
1, 2CompletedSupportive CareBreast Cancer / Drug/Agent Toxicity by Tissue/Organ1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Cutaneous T-Cell Lymphoma (CTCL) / Peripheral T Cell Lymphoma Unspecified / Peripheral T-cell Lymphoma Unspecified1
1, 2CompletedTreatmentBreast Cancer9
1, 2CompletedTreatmentBreast Cancer / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Ovarian Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentBreast Cancer / Lung Cancers / Malignant Gliomas / Melanoma / Tumors Metastatic to Brain1
1, 2CompletedTreatmentBreast Cancer / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1, 2CompletedTreatmentCancer, Bladder / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentCervical Cancers / Endometrial Cancer / Fallopian Tube Cancer / Ovarian Cancer / Sarcomas1
1, 2CompletedTreatmentDose Escalation: Solid Tumors / MTD: Soft Tissue Sarcomas1
1, 2CompletedTreatmentFallopian Tube Cancer / Female Reproductive Cancer / Recurrent Breast Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Breast Cancer / Stage IV Ovarian Epithelial Cancer1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / Marginal Zone Lymphoma (MZL)1
1, 2CompletedTreatmentGlioblastomas1
1, 2CompletedTreatmentHER2 Positive Breast Cancers / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentHepatocellular,Carcinoma1
1, 2CompletedTreatmentHodgkins Disease (HD)1
1, 2CompletedTreatmentHormone-Resistant Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2CompletedTreatmentLocally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS)1
1, 2CompletedTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1, 2CompletedTreatmentMalignant Lymphomas5
1, 2CompletedTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMetastatic Breast Cancer1
1, 2CompletedTreatmentMultiple Myeloma (MM)2
1, 2CompletedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentOvarian Cancer, Primary Peritoneal Cancer1
1, 2CompletedTreatmentPlatinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p531
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentRecurrent Ovarian Cancer1
1, 2CompletedTreatmentRefractory Mantle Cell Lymphoma1
1, 2CompletedTreatmentSarcomas4
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentALK-Positive Anaplastic Large Cell Lymphoma / EBV-Positive DLBCL, Nos / Follicular Lymphoma Grade IIIb / High-grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas / Bone Cancer / Bone Metastases / Bone Neoplasms / Breast Cancer / Cancer, Bladder / Glioblastoma Multiforme (GBM) / Malignancies / Malignancies Multiple / Malignant Gliomas / Malignant Lymphomas / Malignant Neoplasm of Pancreas / Neoplasm of Bone / Neoplasm of Lung / Neoplasms Metastasis / Neoplasms Pancreatic / Neoplasms, Breast / Neoplasms, Colorectal / Neoplasms, Pancreatic / Ovarian Cancer / Refractory Brain Tumor / Refractory Cancer / Refractory Neoplasm / Refractory Non-Hodgkin's lymphoma / Renal Cancers / Resistant Cancer / Sarcomas1
1, 2RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentAdvanced Malignancies1
1, 2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / B-Cell Non-Hodgkin Lymphomas(NHL) / CD20 Positive / Diffuse Large B-Cell Lymphoma Unclassifiable / Intravascular Large B-Cell Lymphoma / Primary Mediastinal (Thymic) Large B-cell Lymphoma / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentB-Cell Non-Hodgkin Lymphomas(NHL)1
1, 2RecruitingTreatmentBreast Cancer1
1, 2RecruitingTreatmentChondrosarcomas / Retroperitoneal Leiomyosarcoma / Retroperitoneal Liposarcoma1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL) / Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentERBB2 Gene Amplification / Estrogen Receptor Positive / Inflammatory Breast Carcinoma / Malignant Neoplasm of Breast / Metastatic Breast Carcinoma / Progesterone Receptor Positive / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer AJCC v6 and v71
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentLymphoma, Hodgkins1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentOvarian Cancer1
1, 2RecruitingTreatmentOvarian Cancer Metastatic / Triple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentPeritoneal Carcinomatosis1
1, 2RecruitingTreatmentSarcomas1
1, 2SuspendedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2TerminatedTreatmentAdvanced Solid Tumors / Breast Cancer1
1, 2TerminatedTreatmentBreast Cancer / Cancer, Advanced / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas / Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentBreast Cancer / HER2 Positive Breast Cancers1
1, 2TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
1, 2TerminatedTreatmentHER2 Positive Metastatic Breast Cancers1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentLiver Cancer1
1, 2TerminatedTreatmentMale Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentMalignancies / Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentMetastatic Breast Cancer1
1, 2TerminatedTreatmentMultiple Myeloma (MM)2
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2TerminatedTreatmentOvarian Cancer1
1, 2TerminatedTreatmentProstate Cancer1
1, 2TerminatedTreatmentRefractory Lymphomas / Relapsed Lymphomas1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2TerminatedTreatmentAdvanced thymic carcinoma / Thymic Carcinoma1
1, 2Unknown StatusTreatmentBreast Cancer1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
1, 2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
1, 2WithdrawnTreatmentBreast Cancer1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentMalignancies1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
1, 2WithdrawnTreatmentOvarian Cancer1
2Active Not RecruitingOtherBreast Cancer / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingPreventionMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Acute Lymphoblastic Leukaemias (ALL) / BCR-ABL1 Fusion Protein Expression / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias / Philadelphia Chromosome Positive / T(9;22)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / Burkitt's Lymphoma / CD20 Positive / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Leukemias / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute Lymphocytic Leukemia (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdvanced Ovarian Cancer1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2Active Not RecruitingTreatmentAnn Arbor Stage II Diffuse Large B-Cell Lymphoma / Ann Arbor Stage III Diffuse Large B-Cell Lymphoma / Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma / CD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentBlastoid Variant Mantle Cell Lymphoma / CD20 Positive / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / Pleomorphic Variant Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentBreast Cancer16
2Active Not RecruitingTreatmentBreast Cancer / Early Breast Cancer / Stage II Breast Cancer / Stage III Breast Cancer1
2Active Not RecruitingTreatmentCancer, Bladder1
2Active Not RecruitingTreatmentClassical Hodgkin's Lymphoma2
2Active Not RecruitingTreatmentClassical Hodgkin's Lymphoma / Lymphocyte-Depleted Classical Hodgkin Lymphoma / Lymphocyte-Rich Classical Hodgkin Lymphoma / Mixed Cellularity Classical Hodgkin Lymphoma / Nodular Sclerosis Classical Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdvanced thymic carcinoma / Clinical Masaoka Stage II to IVA / Clinical Masaoka Stage II-IVA / Thymic Carcinoma1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma Unclassifiable / Malignant Lymphomas1
2Active Not RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2Active Not RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Triple-Negative Breast Carcinoma1
2Active Not RecruitingTreatmentEwing's Sarcoma (ES)1
2Active Not RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer1
2Active Not RecruitingTreatmentHER2 Positive Breast Cancers1
2Active Not RecruitingTreatmentHIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentHepatic Metastases / Metastases / Neuroendocrine Tumors1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma2
2Active Not RecruitingTreatmentHodgkins Disease (HD)2
2Active Not RecruitingTreatmentInflammatory carcinoma of the breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentLarge B-cell Diffuse Lymphoma of Testis / Primary Testicular Diffuse Large B-cell Lymphoma1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2Active Not RecruitingTreatmentLymphoma, B-Cell1
2Active Not RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-cell type lymphoma1
2Active Not RecruitingTreatmentLymphoma, Hodgkins5
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentMalignant Lymphomas8
2Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL) / Untreated1
2Active Not RecruitingTreatmentMetastatic Breast Cancer1
2Active Not RecruitingTreatmentMetastatic Sarcoma1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentPrimary Mediastinal Large B Cell Lymphoma / Primary mediastinal large B-cell lymphomas1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSinonasal Tumors1
2Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentSoft Tissue Sarcoma, Adult / Soft Tissue Sarcoma, Child1
2Active Not RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2Active Not RecruitingTreatmentThyroid Cancers1
2Active Not RecruitingTreatmentUnresectable Sinonasal Tumors1
2CompletedBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedPreventionOral Mucositis / Sarcomas1
2CompletedSupportive CareChemotherapy Induced Neutropenia1
2CompletedSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Neuroblastomas / Soft Tissue Sarcoma (STS) / Wilms' tumor1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of GE Junction / Adenocarcinoma of Stomach1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdrenocortical Carcinoma / Brain and Central Nervous System Tumors / Head and Neck Carcinoma / Liver Cancer / Mesothelioma, Malignant / Pheochromocytomas / Sarcomas1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentB-All / Burkitt's Lymphoma1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Adult Acute Lymphoblastic Leukemia (ALL) / Ph Positive Adult Acute Lymphoblastic Leukemia / Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia (ALL) / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia (ALL)1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBreast Cancer53
2CompletedTreatmentBreast Cancer / Cardiac Toxicity1
2CompletedTreatmentBreast Cancer / Cognitive/Functional Effects / Depression / Malnutrition / Psychosocial Effects of Cancer and Its Treatment1
2CompletedTreatmentBreast Cancer / Early Breast Cancer / Stage II Breast Cancer1
2CompletedTreatmentBreast Cancer / Elderly1
2CompletedTreatmentBreast Cancer / Fevers / Neutropenia1
2CompletedTreatmentBreast Cancer / HER2 Negative Breast Cancer / HER2-Negative Breast Cancer1
2CompletedTreatmentBreast Cancer / Inflammatory carcinoma of the breast / Locally Advanced Breast Cancer (LABC)1
2CompletedTreatmentBreast Cancer / Metastatic Breast Cancer1
2CompletedTreatmentBreast Cancer / Neoplasms Metastasis1
2CompletedTreatmentBreast Cancer / Neoplasms, Breast3
2CompletedTreatmentBreast Cancer / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentBreast Cancer / Stage II Breast Cancer / Stage III Breast Cancer1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer of the Ovary Treated as 2nd Line Therapy / Cervical Cancers / Muellerian Mixed Tumours / Non-Epithelial Ovarian Tumours / Tumours of the Uterus1
2CompletedTreatmentCancer, Bladder2
2CompletedTreatmentCancer, Bladder / Muscle-invasive Bladder Cancer1
2CompletedTreatmentCancer, Bladder / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentCarcinoma, Adrenal Cortical1
2CompletedTreatmentCarcinosarcoma / Leiomyosarcomas / Mesenchymal Tumor1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2CompletedTreatmentClassic Hodgkin Lymphoma / Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 / Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8 / Lymphoma, Hodgkins1
2CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
2CompletedTreatmentDiffuse Large Cell Lymphoma1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Bladder Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentEarly Triple Negative Breast Cancer1
2CompletedTreatmentEndometrial Cancer4
2CompletedTreatmentEndometrial Cancer / Fallopian Tube Cancer / Ovarian Cancer / Sarcomas1
2CompletedTreatmentEndometrial Cancer / Sarcomas1
2CompletedTreatmentEstrogen Receptor Positive Breast Cancer / Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2 Positive Breast Cancers / Progesterone Receptor Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentEstrogen Receptor Positive Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2 Positive Breast Cancers / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / HER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Non-rhabdomyosarcoma Soft-tissue Sarcoma1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Ovarian Cancer1
2CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentFollicular Lymphoma (FL)2
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHepatocellular,Carcinoma2
2CompletedTreatmentHer2-normal / Her2normal1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHigh-grade Serous Ovarian Cancer1
2CompletedTreatmentHodgkins Disease (HD) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentInflammatory carcinoma of the breast / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedTreatmentInvasive Breast Cancer1
2CompletedTreatmentIslet Cell Adenoma / Neoplasms Metastasis / Zollinger-Ellison Syndrome1
2CompletedTreatmentKaposi s Sarcoma (KS)1
2CompletedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2CompletedTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2CompletedTreatmentLeukemias5
2CompletedTreatmentLeukemias / Malignant Lymphomas4
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Neutropenia / Thrombocytopenia1
2CompletedTreatmentLiver Cancer4
2CompletedTreatmentLiver Cancer / Metastatic Cancers1
2CompletedTreatmentLymphoma, B-Cell2
2CompletedTreatmentLymphoma, Diffuse Large-Cell1
2CompletedTreatmentLymphoma, Hodgkins3
2CompletedTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)4
2CompletedTreatmentLymphoma, T-Cell, Peripheral1
2CompletedTreatmentMale Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2CompletedTreatmentMalignancies / Ovarian Cancer1
2CompletedTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Sarcoma, Osteogenic1
2CompletedTreatmentMalignant Lymphomas49
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMalignant Lymphomas / Neurologic toxicity1
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMalignant Neoplasm of Stomach2
2CompletedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2CompletedTreatmentMantle Cell Lymphoma (MCL)3
2CompletedTreatmentMesothelioma, Malignant1
2CompletedTreatmentMetastatic Adult Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Bone Sarcomas1
2CompletedTreatmentMetastatic Breast Cancer4
2CompletedTreatmentMetastatic Cancers / Prostate Cancer1
2CompletedTreatmentMetastatic Cancers / Sarcomas1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma / Renal Cell Carcinoma With Sarcomatoid Features1
2CompletedTreatmentMultiple Myeloma (MM)13
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
2CompletedTreatmentNeoplasms, Breast7
2CompletedTreatmentNeoplasms, Ovarian6
2CompletedTreatmentNeuroblastomas12
2CompletedTreatmentNeurofibromatosis Type 1 / Sarcomas1
2CompletedTreatmentNeutropenia / Sarcomas1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentOvarian Cancer8
2CompletedTreatmentOvarian Cancer Metastatic Recurrent1
2CompletedTreatmentOvarian Cancer / Sarcomas1
2CompletedTreatmentOvarian Cancer / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentOvarian Epithelial Cancer1
2CompletedTreatmentPosttransplant Lymphoproliferative Disorder / PTLD1
2CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)3
2CompletedTreatmentPeritoneal Carcinomatosis1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentProstate Cancer / Thromboembolism1
2CompletedTreatmentProstatic Neoplasms1
2CompletedTreatmentProsthesis Survival1
2CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Salivary Gland Adenoid Cystic Carcinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer1
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentRecurrent Ovarian Cancer1
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRenal Cancers / Sarcomas1
2CompletedTreatmentRetinoblastoma1
2CompletedTreatmentSarcoma, Osteogenic2
2CompletedTreatmentSarcomas10
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)2
2CompletedTreatmentSoft Tissue Leiomyosarcoma / Uterus Leiomyosarcoma1
2CompletedTreatmentSoft Tissue Sarcoma (STS)2
2CompletedTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentTriple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
2CompletedTreatmentUntreated T-Cell Angioimmunoblastic Lymphoma1
2Not Yet RecruitingTreatmentAdvanced Hodgkin's Lymphoma1
2Not Yet RecruitingTreatmentAnaplastic Kidney Wilms Tumor / Recurrent Kidney Wilms Tumor / Stage II Kidney Wilms Tumor / Stage III Kidney Wilms Tumor / Stage IV Kidney Wilms Tumor1
2Not Yet RecruitingTreatmentBladder Urothelial Carcinoma / Stage III Bladder Cancer AJCC v8 / Stage IIIA Bladder Cancer AJCC v8 / Stage IIIB Bladder Cancer AJCC v81
2Not Yet RecruitingTreatmentBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)1
2Not Yet RecruitingTreatmentEarly Breast Cancer1
2Not Yet RecruitingTreatmentHeptocellular Cancer / Heptocellular Carcinoma / Metastatic Hepatocellular Carcinoma1
2Not Yet RecruitingTreatmentInvasive Breast Cancer1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Malignancies1
2Not Yet RecruitingTreatmentMalignant Soft Tissue Sarcoma1
2Not Yet RecruitingTreatmentRecurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma1
2Not Yet RecruitingTreatmentRecurrent, Platinum-resistant Ovarian Cancer1
2Not Yet RecruitingTreatmentRichter's Syndrome1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)2
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
2RecruitingSupportive CareLocally Advanced Sarcoma / Sarcomas1
2RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / AIDS-Related Burkitt Lymphoma / Atypical Burkitt/Burkitt-Like Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / Leukemias / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Burkitt Lymphoma / Refractory Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Burkitt Lymphoma / Refractory Childhood Acute Lymphoblastic Leukemia1
2RecruitingTreatmentALL (Acute Lymphoblastic Leukemia) / B-cell Acute Lymphoblastic Leukemia / Leukemias1
2RecruitingTreatmentAbdominal wall neoplasm / Chemotherapeutic Toxicity / Chemotherapy Effect / Histologic Progression / Metastases to peritoneum / Peritoneum; Carcinomatosis / Quality of Life1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias / Philadelphia Chromosome Positive / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Lymphoma, Lymphoblastic / Philadelphia Chromosome Positive1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Leukemias1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Lymphoma, Lymphoblastic / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAdvanced Breast Cancer1
2RecruitingTreatmentAdvanced Soft Tissue Sarcoma1
2RecruitingTreatmentAdvanced Soft Tissue Sarcoma / Metastatic Soft Tissue Sarcoma1
2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Transformed Non-Hodgkin Lymphoma1
2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Bilateral Thalamic Glioma / Brainstem Glioma, Pediatric / Diffuse Spinal Glioma / DIPG / Glioblastomas (GBM) / Gliomatosis Cerebri / Midline Diffuse Glioma1
2RecruitingTreatmentAngioimmunoblastic T-Cell Lymphoma1
2RecruitingTreatmentAnn Arbor Stage I Hodgkin Lymphoma / Ann Arbor Stage I Lymphocyte-Depleted Classic Hodgkin Lymphoma / Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma / Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma / Ann Arbor Stage IA Hodgkin Lymphoma / Ann Arbor Stage IB Hodgkin Lymphoma / Ann Arbor Stage II Hodgkin Lymphoma / Ann Arbor Stage II Lymphocyte-Depleted Classic Hodgkin Lymphoma / Ann Arbor Stage II Mixed Cellularity Classic Hodgkin Lymphoma / Ann Arbor Stage II Nodular Sclerosis Classic Hodgkin Lymphoma / Ann Arbor Stage IIA Hodgkin Lymphoma / Ann Arbor Stage IIB Hodgkin Lymphoma / Classic Hodgkin Lymphoma / Lymphocyte-Rich Classic Hodgkin Lymphoma1
2RecruitingTreatmentAnn Arbor Stage I Hodgkin Lymphoma / Ann Arbor Stage IA Hodgkin Lymphoma / Ann Arbor Stage IB Hodgkin Lymphoma / Ann Arbor Stage II Hodgkin Lymphoma / Ann Arbor Stage IIA Hodgkin Lymphoma / Ann Arbor Stage IIB Hodgkin Lymphoma / Classic Hodgkin Lymphoma / Stage I Hodgkin Lymphoma / Stage IA Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentB Acute Lymphoblastic Leukemia / CRLF2 Positive / Leukemias / Recurrent Ph-Like Acute Lymphoblastic Leukemia / Refractory Ph-Like Acute Lymphoblastic Leukemia1
2RecruitingTreatmentB-Cell Non-Hodgkin Lymphomas(NHL)1
2RecruitingTreatmentBRCA1 Hereditary Breast and Ovarian Cancer Syndrome1
2RecruitingTreatmentBladder Adenocarcinoma / Bladder Mixed Adenocarcinoma / Bladder Squamous Cell Carcinoma / Bladder Urothelial Carcinoma / Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant / Infiltrating Bladder Urothelial Carcinoma With Giant Cells / Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation / Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation / Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant / Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant / Infiltrating Bladder Urothelial Carcinoma, Nested Variant / Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant1
2RecruitingTreatmentBreast Adenocarcinoma / Breast Cancer Stage II / Breast Cancer Stage III / Carcinoma Breast Stage IV / Estrogen Receptor Positive Breast Cancer / Estrogen Receptor- Negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Invasive Adenocarcinoma of the Breast / Invasive Breast Carcinoma / Locally Advanced Breast Cancer (LABC) / Progesterone Receptor Negative / Progesterone Receptor Positive Tumor / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBreast Cancer5
2RecruitingTreatmentBreast Cancer Stage II / Breast Cancer Stage III1
2RecruitingTreatmentBreast Cancer / Estrogen Receptor Negative / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBreast Cancer / Estrogen Receptor Positive Breast Cancer / Estrogen Receptor-Positive Breast Cancer1
2RecruitingTreatmentBreast Cancer / Hemangiosarcoma / Neoplasms, Breast / Tumors, Breast1
2RecruitingTreatmentBreast Cancer / Hormone Receptor Positive Tumor / Luminal B / Metastatic Breast Cancer1
2RecruitingTreatmentBreast Cancer / Invasive Breast Cancer1
2RecruitingTreatmentBreast Cancer / Neoadjuvant Chemotherapy1
2RecruitingTreatmentBreast Cancer / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCD20 Positive / Mantle Cell Lymphoma (MCL)1
2RecruitingTreatmentCarcinoma, Small Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neuroendocrine Tumors / Ovarian Epithelial Cancer / Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentCervical Cancers1
2RecruitingTreatmentClassical Hodgkin's Lymphoma1
2RecruitingTreatmentClassical Hodgkin's Lymphoma / Hodgkin Lymphoma (Category) / Hodgkins Disease (HD) / Lymphoma, Hodgkins1
2RecruitingTreatmentDisorders, Lymphoproliferative / HHV-8 / Human Immunodeficiency Virus (HIV) Infections / Malignancies1
2RecruitingTreatmentDouble Expressor Lymphoma1
2RecruitingTreatmentEBV-Positive DLBCL, Nos1
2RecruitingTreatmentEarly Breast Cancer1
2RecruitingTreatmentEndometrial Clear Cell Carcinoma / Ovarian Clear Cell Carcinoma1
2RecruitingTreatmentEpithelioid Sarcoma / Fibrosarcomas malignant / Hemangiosarcoma / Leiomyosarcomas / Liposarcoma / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Myxofibrosarcoma / Soft Tissue Sarcoma (STS) / Synovial Sarcoma / Undifferentiated Pleomorphic Sarcoma1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / Estrogen Receptor Positive Breast Cancer / Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2 Negative Breast Cancer / HER2 Positive Breast Cancers / HER2-Negative Breast Cancer / HER2/Neu Negative / HER2/Neu Positive / Invasive Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Progesterone Receptor Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC) / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentExperimental Tumor1
2RecruitingTreatmentFallopian Tube Cancer / Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer1
2RecruitingTreatmentFallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Clear Cell Tumor / Malignant Ovarian Endometrioid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Ovarian Serous Tumor / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2RecruitingTreatmentGanglioneuroblastoma / High-Risk Neuroblastoma / NMYC Gene Amplification1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentHER2 Positive Breast Cancers1
2RecruitingTreatmentHHV-8 / KSHV / KSHV Inflammatory Cytokine Syndrome (KICS)1
2RecruitingTreatmentHigh Grade Serous Carcinoma / Ovarian Neoplasm Epithelial1
2RecruitingTreatmentHigh-grade B-cell Lymphoma / Lymphoma, B Cell / Lymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas1
2RecruitingTreatmentHigh-grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma1
2RecruitingTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast / Inflammatory carcinoma of the breast1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentInflammatory carcinoma of the breast1
2RecruitingTreatmentKidney Medullary Carcinoma / Metastatic Kidney Medullary Carcinoma / Metastatic Renal Cell Carcinoma / SMARCB1 Negative / Stage III Renal Cell Cancer AJCC v8 / Stage IV Renal Cell Cancer AJCC v81
2RecruitingTreatmentLarge B Cell Lymphoma1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentLocally Advanced Breast Cancer (LABC)1
2RecruitingTreatmentLocally Advanced Malignant Solid Neoplasm / Metastatic Malignant Solid Neoplasm / Progressive Disease1
2RecruitingTreatmentLymphoma, Hodgkins5
2RecruitingTreatmentLymphoma, Hodgkins / Relapsed or Refractory Hodgkin Lymphoma1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)9
2RecruitingTreatmentMalignant Neoplasm of Female Breast1
2RecruitingTreatmentMetastatic Adult Soft Tissue Sarcoma / Recurrent Adult Soft Tissue Sarcoma1
2RecruitingTreatmentMetastatic Breast Cancer2
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentMuscle Invasive Bladder Cancer1
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentNon Metastatic Disease / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentOvarian Cancer1
2RecruitingTreatmentOvarian Epithelial Cancer1
2RecruitingTreatmentPatients With Diagnosis of Unresectable or Metastatic Soft Tissue Sarcoma / Unresectable or Metastatic Soft Tissue Sarcoma1
2RecruitingTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentRetinoblastoma1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)3
2RecruitingTreatmentSolitary Fibrous Tumors1
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentBreast Cancer1
2SuspendedTreatmentBreast Cancer / Triple Negative Breast Cancer (TNBC)1
2TerminatedPreventionBreast Cancer / Tumors, Breast1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBreast Cancer8
2TerminatedTreatmentBreast Cancer / Cancer of the Breast / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentBreast Cancer / Neoplasms Metastasis1
2TerminatedTreatmentBurkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Primary Effusion Lymphomas1
2TerminatedTreatmentCancer, Bladder3
2TerminatedTreatmentCarcinoma NOS / Metastatic Cancers / Neoplasms, Thyroid / Thyroid Cancers1
2TerminatedTreatmentCardiac Toxicity / Sarcomas1
2TerminatedTreatmentCerebral Lymphoma B Cell Refractory1
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentColon Cancer Liver Metastasis1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2TerminatedTreatmentDuctal Carcinoma1
2TerminatedTreatmentEarly Breast Cancer1
2TerminatedTreatmentEndometrial Cancer1
2TerminatedTreatmentEpithelial Ovarian Carcinoma1
2TerminatedTreatmentEpstein Barr Virus Associated Hodgkin's Lymphoma / Epstein Barr Virus Associated Non Hodgkin's Lymphoma / Post-transplant Lymphoproliferative Disease (PTLD)1
2TerminatedTreatmentEwing's Sarcoma (ES)1
2TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentFallopian Tube Cancer / Recurrent Ovarian Cancer1
2TerminatedTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma / DLBCL1
2TerminatedTreatmentHER2 Negative Breast Cancer / HER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2TerminatedTreatmentHepatocellular Cancer / Neoplasms, Hepatic1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLiver Cancer1
2TerminatedTreatmentLocally Advanced HER2-negative Breast Cancer1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Hodgkins1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Lymphomas4
2TerminatedTreatmentMalignant Neoplasm of Pancreas2
2TerminatedTreatmentMetastatic Breast Cancer2
2TerminatedTreatmentMetastatic Cancers / Prostate Cancer1
2TerminatedTreatmentMultiple Myeloma (MM)3
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2TerminatedTreatmentOvarian Cancer1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentProstate Cancer2
2TerminatedTreatmentProstatic Neoplasms1
2TerminatedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma AJCC v7 / Stage II Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma AJCC v7 / Stage III Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma AJCC v71
2TerminatedTreatmentRefractory Multiple Myeloma1
2TerminatedTreatmentRefractory Nasopharyngeal Carcinoma1
2TerminatedTreatmentSarcomas4
2TerminatedTreatmentSarcomas / Soft Tissue Sarcoma (STS)1
2TerminatedTreatmentSoft Tissue Sarcoma (STS)1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentUnresectable Intrahepatic Cholangiocarcinoma1
2Unknown StatusNot AvailableHepatocellular,Carcinoma1
2Unknown StatusTreatmentAggressive Non-Hodgkin's Lymphoma in the Elderly1
2Unknown StatusTreatmentAutoimmune Thrombocytopenic Purpura1
2Unknown StatusTreatmentBreast Cancer13
2Unknown StatusTreatmentBreast Cancer / Breast Diseases / Neoplasms / Neoplasms by Site1
2Unknown StatusTreatmentBreast Cancer / Cervical Cancers / Endometrial Cancer / Ovarian Cancer1
2Unknown StatusTreatmentCancer of the Gallbladder / Extrahepatic Bile Duct Cancer / Liver Cancer1
2Unknown StatusTreatmentEndometrial Cancer1
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentHepatocellular,Carcinoma2
2Unknown StatusTreatmentHodgkins Disease (HD)1
2Unknown StatusTreatmentLeukemia, Lymphocytic1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentLeukemias2
2Unknown StatusTreatmentLiver Cancer3
2Unknown StatusTreatmentLocally Advanced Soft Tissue Sarcoma / Metastatic Soft Tissue Sarcoma / Unresectable Soft Tissue Sarcoma1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentMalignant Lymphomas11
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentMalignant Pleural Mesothelioma (MPM)1
2Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentMetastatic Breast Cancer2
2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentNeuroblastomas2
2Unknown StatusTreatmentOvarian Cancer1
2Unknown StatusTreatmentOvarian Cancer / Sarcomas / Small Intestine Cancer1
2Unknown StatusTreatmentPain / Prostate Cancer1
2Unknown StatusTreatmentPleural Mesotheliomas1
2Unknown StatusTreatmentRenal Cancers2
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)2
2Unknown StatusTreatmentNonleukemic meningeal cancer1
2WithdrawnTreatmentAdenocarcinomas / Carcinoma, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Painful Bone Metastases / Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentBreast Cancer5
2WithdrawnTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2WithdrawnTreatmentMalignant Lymphomas4
2WithdrawnTreatmentMultiple Myeloma (MM)3
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNeoplasms, Endometrial1
2WithdrawnTreatmentNeoplasms, Hepatic1
2WithdrawnTreatmentOvarian Cancer1
2WithdrawnTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage IIB Adult Soft Tissue Sarcoma / Stage IIC Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IVA Adult Soft Tissue Sarcoma1
2WithdrawnTreatmentTriple Negative Breast Cancer (TNBC)1
2, 3Active Not RecruitingTreatmentAdult Fibrosarcoma / Alveolar Soft Part Sarcoma (ASPS) / Angiomatoid Fibrous Histiocytoma / Atypical Fibroxanthoma / Chondrosarcoma, Mesenchymal / Clear Cell Sarcoma of Soft Tissue / Epithelioid Malignant Peripheral Nerve Sheath Tumor / Epithelioid Sarcoma / Extraskeletal Myxoid Chondrosarcoma / Extraskeletal osteosarcomas / Fibrohistiocytic Neoplasm / Fibrosarcomas malignant / Glomus Tumor of the Skin / Inflammatory Myofibroblastic Tumors / Intimal Sarcoma / Leiomyosarcomas / Liposarcoma / Low Grade Fibromyxoid Sarcoma / Low Grade Myofibroblastic Sarcoma / Malignant Cutaneous Granular Cell Tumor / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Malignant Triton Tumor / Myxofibrosarcoma / Myxoid Chondrosarcoma / Myxoinflammatory Fibroblastic Sarcoma / Nerve Sheath Neoplasm / PEComa / Pericytic Neoplasm / Plexiform Fibrohistiocytic Tumor / Sclerosing Epithelioid Fibrosarcoma / Stage IB Soft Tissue Sarcoma / Stage IB Soft Tissue Sarcoma AJCC v7 / Stage IIB Soft Tissue Sarcoma / Stage IIB Soft Tissue Sarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Synovial Sarcoma / Undifferentiated (Embryonal) Sarcoma / Undifferentiated High Grade Pleomorphic Sarcoma of Bone1
2, 3Active Not RecruitingTreatmentBreast Cancer1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3Active Not RecruitingTreatmentLow Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Low Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Primary Peritoneal Serous Adenocarcinoma1
2, 3Active Not RecruitingTreatmentSarcoma, Osteogenic1
2, 3CompletedSupportive CareChemotherapy Induced Neutropenia1
2, 3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of breast stage IV / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2, 3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / Leukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell / Leukemias / Lymphoma, Lymphoblastic1
2, 3RecruitingTreatmentBCL2 Gene Translocation / C-Myc Translocation / Double Expressor Lymphoma / Double-Expressor Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present1
2, 3RecruitingTreatmentBreast Cancer / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentChildhood Hepatocellular Carcinoma / Childhood Malignant Liver Neoplasm / Elevated Alpha-Fetoprotein / Fibrolamellar Carcinoma / Hepatoblastomas / Hepatocellular Malignant Neoplasm, Not Otherwise Specified / SMARCB1 Gene Mutation1
2, 3RecruitingTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Fallopian Tube Undifferentiated Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Ovarian Undifferentiated Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2, 3RecruitingTreatmentLeukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell1
2, 3RecruitingTreatmentLeukemias1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentOverall Survival / Progression-free Survival / Therapeutic Agent Toxicity1
2, 3SuspendedTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Undifferentiated Carcinoma / High Grade Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Undifferentiated Carcinoma / Platinum-Resistant Ovarian Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2, 3TerminatedTreatmentHepatocellular,Carcinoma1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3TerminatedTreatmentSarcomas1
2, 3Unknown StatusNot AvailableBreast Cancer1
2, 3Unknown StatusTreatmentAdjuvant / Cancer treatment / Neoplasms, Breast1
2, 3Unknown StatusTreatmentBreast Cancer1
2, 3Unknown StatusTreatmentHepatocellular,Carcinoma1
2, 3Unknown StatusTreatmentSarcoma, Osteogenic1
2, 3WithdrawnTreatmentHepatocellular,Carcinoma1
3Active Not RecruitingNot AvailableBreast Cancer1
3Active Not RecruitingPreventionHepatocellular,Carcinoma1
3Active Not RecruitingSupportive CareHematopoietic/Lymphoid Cancer / Nausea and vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Lymphoblastic Lymphoma / Ann Arbor Stage I B Lymphoblastic Lymphoma / Ann Arbor Stage II B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Hypodiploid B Acute Lymphoblastic Leukemia / Intrachromosomal Amplification of Chromosome 21 / Philadelphia Chromosome Positive / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Non-Resectable Hepatocellular Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Hepatocellular Carcinoma / Stage III Hepatocellular Carcinoma AJCC v7 / Stage IIIA Hepatocellular Carcinoma AJCC v7 / Stage IIIB Hepatocellular Carcinoma AJCC v7 / Stage IIIC Hepatocellular Carcinoma AJCC v7 / Stage IV Hepatocellular Carcinoma AJCC v7 / Stage IVA Hepatocellular Carcinoma AJCC v7 / Stage IVB Hepatocellular Carcinoma AJCC v7 / Unresectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentAdult Kidney Wilms Tumor / Adult Renal Wilms Tumor / Beckwith-Wiedemann Syndrome / Childhood Kidney Wilms Tumor / Childhood Renal Wilms Tumor / Diffuse Hyperplastic Perilobar Nephroblastomatosis / Hemihypertrophy / Rhabdoid Tumors of the Kidney (RTK) / Stage I Kidney Wilms Tumor / Stage I Renal Wilms Tumor / Stage II Kidney Wilms Tumor / Stage II Renal Wilms Tumor / Stage III Kidney Wilms Tumor / Stage III Renal Wilms Tumor / Stage IV Kidney Wilms Tumor / Stage IV Renal Wilms Tumor / Stage V Kidney Wilms Tumor / Stage V Renal Wilms Tumor1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Non-Metastatic Extraskeletal Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentAlpha Fetoprotein Increased / PRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-cell type lymphoma1
3Active Not RecruitingTreatmentAnn Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Childhood Hodgkin Lymphoma / Classic Hodgkin Lymphoma / Classical Hodgkin's Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3Active Not RecruitingTreatmentB-Cell Non-Hodgkin Lymphomas(NHL) / Mature B-cell Leukemia Burkitt-type1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentBRCA Rearrangement / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Fallopian Tube Undifferentiated Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Tumor / Ovarian Seromucinous Carcinoma / Ovarian Serous Tumor / Ovarian Transitional Cell Carcinoma / Ovarian Undifferentiated Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Endometrioid Adenocarcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / HER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IA Breast Cancer AJCC v7 / Stage IB Breast Cancer / Stage IB Breast Cancer AJCC v7 / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v71
3Active Not RecruitingTreatmentBreast Cancer10
3Active Not RecruitingTreatmentCancer, Bladder1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentEarly Breast Cancer1
3Active Not RecruitingTreatmentEarly Primary Breast Cancer / Early Primary Breast Cancer in the Elderly1
3Active Not RecruitingTreatmentEndometrial Cancer / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer AJCC v7 / Stage IIIB Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer AJCC v7 / Stage IIIC Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer AJCC v71
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IA Breast Cancer AJCC v7 / Stage IB Breast Cancer / Stage IB Breast Cancer AJCC v7 / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v71
3Active Not RecruitingTreatmentEwing's Sarcoma (ES)1
3Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Ovarian Epithelial Cancer / Primary Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma (MZL) / Small Lymphocytic Lymphoma1
3Active Not RecruitingTreatmentFollicular Non-Hodgkin's Lymphoma1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma / Non-Resectable Hepatocellular Carcinoma / Unresectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentInfiltrating Urothelial Carcinoma / KRAS Gene Mutation1
3Active Not RecruitingTreatmentInvasive Breast Cancer1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemias1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Bone Sarcomas1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLymphoma, Hodgkins5
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentMalignant Lymphomas8
3Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)3
3Active Not RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)2
3Active Not RecruitingTreatmentNeoplasms, Endometrial1
3Active Not RecruitingTreatmentNeuroblastomas1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentOvarian Cancer4
3Active Not RecruitingTreatmentRecurrent Ovarian Cancer1
3Active Not RecruitingTreatmentRetinal Neoplasms / Retinoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
3Active Not RecruitingTreatmentStage I Uterine Sarcoma / Stage I Uterine Sarcoma AJCC v7 / Uterine Corpus Leiomyosarcoma1
3Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)1
3Active Not RecruitingTreatmentTriple Negative Breast Neoplasms1
3CompletedNot AvailablePrimary Breast Cancer1
3CompletedSupportive CareBreast Cancer1
3CompletedSupportive CareBreast Cancer / Chemotherapy Induced Neutropenia1
3CompletedSupportive CareBreast Cancer / Drug/Agent Toxicity by Tissue/Organ / Endometrial Cancer / Fallopian Tube Cancer / Ovarian Cancer / Peritoneal Cavity Cancer1
3CompletedSupportive CareBreast Cancer / Palmar-plantar Erythrodysesthesia (PPE)1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedSupportive CareChemotherapy Induced Neutropenia1
3CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Cancer / Ovarian Cancer1
3CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Genital Neoplasms, Female / Neoplasms, Ovarian / Pelvic Neoplasms1
3CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAdult Alveolar Soft-part Sarcoma / Adult Angiosarcoma / Adult Epithelioid Sarcoma / Adult Extraskeletal Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Fibrous Histiocytoma / Adult Malignant Hemangiopericytoma / Adult Malignant Mesenchymoma / Adult Neurofibrosarcoma / Adult Synovial Sarcoma / Childhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Metastatic Childhood Soft Tissue Sarcoma / Nonmetastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
3CompletedTreatmentAdvanced Hodgkin Disease1
3CompletedTreatmentBreast Cancer32
3CompletedTreatmentBreast Cancer / Cyclophosphamide / Doxorubicin / High Risk / Positive Nodes1
3CompletedTreatmentCancer of the Fallopian Tube / Malignant Peritoneal Neoplasm / Ovarian Cancer1
3CompletedTreatmentCancer, Bladder2
3CompletedTreatmentCancer, Bladder / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
3CompletedTreatmentCancer, Bladder / Urethral Cancer1
3CompletedTreatmentCarcinoma, Adrenal Cortical1
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas2
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentDiffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentEndometrial Cancer3
3CompletedTreatmentEndometrial Cancer / Metastatic Cancers / Ovarian Cancer / Pheochromocytomas / Renal Cancers / Sarcomas1
3CompletedTreatmentEndometrial Cancer / Ovarian Cancer / Pheochromocytomas / Renal Cancers / Sarcomas1
3CompletedTreatmentEndometrial Cancer / Psychosocial Effects of Cancer and Its Treatment1
3CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer1
3CompletedTreatmentFollicular Lymphoma (FL) / Immunocytomas / Lymphocytic Lymphomas / Marginal Zone Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3CompletedTreatmentHepatocellular,Carcinoma3
3CompletedTreatmentHodgkins Disease (HD)1
3CompletedTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Breast Cancer1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)4
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentKaposi's Sarcoma AIDS Related1
3CompletedTreatmentLeukemias7
3CompletedTreatmentLeukemias / Malignant Lymphomas4
3CompletedTreatmentLiver Cancer2
3CompletedTreatmentLocalised High Grade Osteosarcoma of the Limbs / Sarcoma, Osteogenic1
3CompletedTreatmentLung Cancers2
3CompletedTreatmentLymphoma, Diffuse Large-Cell1
3CompletedTreatmentLymphoma, High-Grade1
3CompletedTreatmentLymphoma, Hodgkins5
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
3CompletedTreatmentLymphoma, T-Cell, Peripheral1
3CompletedTreatmentM-Protein / Multiple Myeloma (MM) / Myeloma Proteins / Plasma Cell Myeloma1
3CompletedTreatmentMalignant Lymphomas22
3CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentMetastatic Bladder Cancer / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentMultiple Myeloma (MM)5
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3CompletedTreatmentMultiple Myeloma de Novo Treatment1
3CompletedTreatmentNeoplasms, Breast4
3CompletedTreatmentNeoplasms, Ovarian2
3CompletedTreatmentNeuroblastomas6
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentOvarian Cancer4
3CompletedTreatmentOvarian Cancer / Peritoneal Cavity Cancer1
3CompletedTreatmentPrimary Peritoneal Carcinoma / Primary Peritoneal Cavity Cancer / Stage III Ovarian Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Cancer / Stage IV Ovarian Epithelial Cancer1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentRenal Cancers2
3CompletedTreatmentSarcomas9
3CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
3CompletedTreatmentSoft Tissue Sarcoma (STS)2
3CompletedTreatmentTumors, Solid1
3Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Not Yet RecruitingTreatmentChemotherapy Effect / Susceptibility, Genetic1
3Not Yet RecruitingTreatmentChildhood Renal Tumor1
3Not Yet RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Unspecified Site1
3Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Not Yet RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL) / Peripheral T-Cell Lymphoma (PTCL)1
3Not Yet RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
3Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3Not Yet RecruitingTreatmentUterine or Soft Tissue Leiomyosarcoma1
3RecruitingOtherInvasive Breast Cancer1
3RecruitingSupportive CareChemotherapy Induced Neutropenia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Mixed Phenotype Acute Leukemia (MPAL) / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric2
3RecruitingTreatmentAdvanced Epithelioid Sarcoma / Advanced Soft Tissue Sarcoma1
3RecruitingTreatmentAnn Arbor Stage III Hodgkin Lymphoma / Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma / Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma / Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma / Ann Arbor Stage IIIA Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma / Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma / Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Classic Hodgkin Lymphoma / Lymphocyte-Rich Classic Hodgkin Lymphoma1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Central Nervous System Leukemia / Mixed Phenotype Acute Leukemia (MPAL) / Testicular Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Down Syndrome (DS)1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentBreast Cancer4
3RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / Ganglioneuroblastoma / INRG Stage L2 / INRG Stage M / INRG Stage MS / Neuroblastomas / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentClassical Hodgkin's Lymphoma1
3RecruitingTreatmentEarly Breast Cancer1
3RecruitingTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentGanglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Neuroblastomas / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma1
3RecruitingTreatmentHER2-Positive Early Breast Cancer1
3RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentHigh-Risk Neuroblastoma1
3RecruitingTreatmentLymphoblastic Lymphoma, Childhood1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic3
3RecruitingTreatmentLymphoma, Hodgkins1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)7
3RecruitingTreatmentLymphoma, Lymphoblastic1
3RecruitingTreatmentMalignant Neoplasm of Breast1
3RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentNeoplasms, Ovarian1
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentNon-metastatic Soft-tissue Sarcoma / Resectable1
3RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
3RecruitingTreatmentRecurrent Ovarian Carcinoma1
3RecruitingTreatmentThalidomide1
3RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3SuspendedTreatmentBreast Cancer1
3SuspendedTreatmentMalignant Lymphomas1
3SuspendedTreatmentOvarian Cancer1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedTreatmentBreast Cancer3
3TerminatedTreatmentCardiac Toxicity / Inflammatory carcinoma of the breast / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
3TerminatedTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3TerminatedTreatmentEndometrial Cancer2
3TerminatedTreatmentLymphoma, B Cell / Lymphoma, B-Cell1
3TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3TerminatedTreatmentLymphoma, Extranodal NK-T-Cell1
3TerminatedTreatmentLymphoma, Large-Cell, Diffuse1
3TerminatedTreatmentMalignant Lymphomas3
3TerminatedTreatmentMetastatic Breast Cancer1
3TerminatedTreatmentMultiple Myeloma (MM)2
3TerminatedTreatmentNeoplasms, Ovarian2
3TerminatedTreatmentOvarian Epithelial Cancer1
3TerminatedTreatmentProstate Cancer2
3Unknown StatusDiagnosticBreast Cancer1
3Unknown StatusSupportive CareUnspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Unknown StatusTreatmentBreast Cancer6
3Unknown StatusTreatmentCancer, Bladder1
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
3Unknown StatusTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Unknown StatusTreatmentExtramedullary Plasmacytoma1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentHepatocellular,Carcinoma1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentLeukemias3
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLiver Cancer2
3Unknown StatusTreatmentLung Cancers2
3Unknown StatusTreatmentLymphoma, Hodgkins1
3Unknown StatusTreatmentMalignant Lymphomas8
3Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
3Unknown StatusTreatmentMesothelioma, Malignant1
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
3Unknown StatusTreatmentNeuroblastomas2
3Unknown StatusTreatmentOvarian Cancer1
3Unknown StatusTreatmentRenal Cancers1
3Unknown StatusTreatmentSarcomas3
3Unknown StatusTreatmentStage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
3Unknown StatusTreatmentStage I Wilms Tumor / Stage II Wilms Tumor / Stage III Wilms Tumor1
3Unknown StatusTreatmentStage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q / Stage IV Wilms Tumor1
3Unknown StatusTreatmentUterine Sarcoma1
3WithdrawnTreatmentHepatocellular,Carcinoma1
3WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3WithdrawnTreatmentSarcomas1
4Active Not RecruitingTreatmentALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma1
4Active Not RecruitingTreatmentBreast Cancer1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)2
4CompletedHealth Services ResearchBreast Cancer1
4CompletedOtherBMI >30 kg/m2 / Breast Cancer1
4CompletedPreventionCarcinoma of Urinary Bladder, Superficial1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentNeoplasms, Breast1
4CompletedTreatmentNeoplasms, Ovarian1
4CompletedTreatmentNon Burkitt / Post-transplant Lymphoproliferative Disease (PTLD)1
4CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
4CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
4Not Yet RecruitingTreatment0.5-14 Year Old Children With Nephroblastoma1
4Not Yet RecruitingTreatmentEfficacy and Safety1
4RecruitingOtherHepato Cellular Carcinoma1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAdvanced Follicular Lymphoma1
4RecruitingTreatmentBreast Cancer2
4RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentNewly Diagnosed Peripheral T-cell Lymphoma1
4RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
4RecruitingTreatmentPediatric Hodgkin's Disease1
4RecruitingTreatmentSoft Tissue Sarcoma (STS)1
4TerminatedTreatmentNeoplasms, Breast2
4Unknown StatusNot AvailableRhabdomyosarcomas1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
4Unknown StatusTreatmentBreast Cancer1
Not AvailableActive Not RecruitingNot AvailableBreast Cancer1
Not AvailableActive Not RecruitingDiagnosticSarcomas1
Not AvailableActive Not RecruitingHealth Services ResearchPleuropulmonary Blastoma1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentChildhood Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
Not AvailableActive Not RecruitingTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableActive Not RecruitingTreatmentLymphoma, Hodgkins1
Not AvailableCompletedNot AvailableBreast Cancer1
Not AvailableCompletedNot AvailableBreast Cancer / Cardiac Toxicity / Cardiovascular Complications1
Not AvailableCompletedNot AvailableBreast Cancer / Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Fatigue / Long-Term Effects Secondary to Cancer Therapy in Adults / Neurologic toxicity / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableCompletedNot AvailableBreast Cancer / Metastatic Cancers1
Not AvailableCompletedNot AvailableLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
Not AvailableCompletedNot AvailableMetastatic Breast Cancer1
Not AvailableCompletedNot AvailableNeoplasms, Breast1
Not AvailableCompletedNot AvailableNeoplasms, Ovarian1
Not AvailableCompletedNot AvailableOvarian Cancer2
Not AvailableCompletedNot AvailableOvarian Carcinoma1
Not AvailableCompletedNot AvailableRecurrent Ovarian Epithelial Cancer1
Not AvailableCompletedNot AvailableSarcoma, Osteogenic / Spindle Cell Sarcoma of Bone1
Not AvailableCompletedDiagnosticCardiac Toxicity / Chemotherapeutic Agent Toxicity / Malignant Lymphomas1
Not AvailableCompletedDiagnosticDoxorubicin Induced Cardiomyopathy / Malignant Neoplasm of Female Breast1
Not AvailableCompletedPreventionSarcomas1
Not AvailableCompletedSupportive CareEarly Breast Cancer / Male Breast Cancer / Nausea and vomiting / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Chemotherapy-Induced Nausea and Vomiting (CINV) / Effects of Chemotherapy / Sarcomas1
Not AvailableCompletedTreatmentAtaxia Telangiectasia (AT) / Ataxia-Telangiectasia1
Not AvailableCompletedTreatmentBreast Cancer7
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentEwing Sarcoma of Bone / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemias1
Not AvailableCompletedTreatmentLymphoma, Hodgkins1
Not AvailableCompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentMalignant Lymphomas2
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentNeuroblastomas1
Not AvailableCompletedTreatmentOsteolymphoma1
Not AvailableCompletedTreatmentOvarian Epithelial Cancer1
Not AvailableCompletedTreatmentSarcomas1
Not AvailableCompletedTreatmentStage IIA Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableNot Yet RecruitingNot AvailableTo Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma1
Not AvailableRecruitingNot AvailableAdult Acute Lymphoblastic Leukemia1
Not AvailableRecruitingNot AvailableBreast Cancer1
Not AvailableRecruitingNot AvailableCancer, Appendiceal / Cervical Cancers / Colorectal Cancers / Fallopian Tube Cancer / Malignant Neoplasm of Stomach / Ovarian Cancer / Primary Peritoneal Carcinoma / Uterine Malignancies1
Not AvailableRecruitingNot AvailableCholangiocarcinomas1
Not AvailableRecruitingNot AvailableDiffuse Large B-Cell / Large B-Cell / Malignant Lymphomas1
Not AvailableRecruitingNot AvailableHepatocellular,Carcinoma1
Not AvailableRecruitingNot AvailableMalignant Lymphomas1
Not AvailableRecruitingNot AvailableSoft Tissue Sarcoma (STS)1
Not AvailableRecruitingTreatmentBreast Cancer / Chemotherapeutic Toxicity1
Not AvailableRecruitingTreatmentCervical Cancers / Uterine Malignancies1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentLiver Cancer1
Not AvailableRecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
Not AvailableRecruitingTreatmentNeuroblastomas1
Not AvailableRecruitingTreatmentOsteosarcoma of Pelvis1
Not AvailableRecruitingTreatmentPeripheral T Cell Lymphoma (PTCL) / Peripheral T-Cell Lymphoma (PTCL)1
Not AvailableRecruitingTreatmentRetroperitoneal Sarcoma1
Not AvailableRecruitingTreatmentStage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
Not AvailableTerminatedNot AvailableBreast Cancer1
Not AvailableTerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
Not AvailableTerminatedTreatmentLymphoma, Hodgkins1
Not AvailableTerminatedTreatmentOvarian Cancer1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableTerminatedTreatmentT-cell type lymphoma1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableUnknown StatusTreatmentBreast Cancer4
Not AvailableUnknown StatusTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Metastatic Cancers1
Not AvailableUnknown StatusTreatmentChemotherapy, Adjuvant / Hepatocellular,Carcinoma / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2
Not AvailableWithdrawnDiagnosticMalignant Lymphomas1
Not AvailableWithdrawnTreatmentBreast Cancer2
Not AvailableWithdrawnTreatmentHepatocellular,Carcinoma2
Not AvailableWithdrawnTreatmentMalignant Lymphomas1

Pharmacoeconomics

Manufacturers
  • Ortho biotech products lp
  • Pharmacia and upjohn co
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmachemie bv
  • Teva parenteral medicines inc
  • Bristol myers squibb co
Packagers
  • Alza Corp.
  • APP Pharmaceuticals
  • APPD
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bristol-Myers Squibb Co.
  • Centocor Ortho Biotech Inc.
  • Mead Johnson and Co.
  • Pfizer Inc.
  • Pharmachemie BV
  • Pharmacia Inc.
  • Schering-Plough Inc.
  • Sopherion Therapeutics LLC
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous2 mg/1mL
Injection, solution, concentrateIntravenous2 mg/ml
SuspensionIntravenous
Injectable, liposomalIntravenous2 mg/1mL
Injection, suspension, liposomalIntravenous2 mg/1mL
Powder, for solutionIntravenous
InjectionIntravenous10 mg/5mL
InjectionIntravenous2 mg/1mL
InjectionIntravenous20 mg/10mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous50 mg/25mL
Injection, powder, lyophilized, for solutionIntra-arterial; Intravenous; Intravesical2 mg/1mL
Injection, powder, lyophilized, for solutionIntravenous10 mg/1
Injection, powder, lyophilized, for solutionIntravenous150 mg/1
Injection, powder, lyophilized, for solutionIntravenous20 mg/1
Injection, powder, lyophilized, for solutionIntravenous50 mg/1
Injection, solutionIntravenous2 mg/1mL
Powder, for solutionIntravenous; Intravesical
SolutionIntravenous
SolutionIntravenous; Intravesical
Injectable, liposomalIntravenous
Injection, powder, for solutionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous100 mg/50mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/25mL
Prices
Unit descriptionCostUnit
Doxorubicin 50 mg vial132.0USD vial
Doxil 2 mg/ml vial115.78USD ml
Adriamycin 50 mg vial64.8USD vial
Doxorubicin 10 mg vial44.4USD vial
Adriamycin 20 mg vial26.4USD vial
Adriamycin 10 mg vial13.2USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5013556No1991-05-072009-10-20Us
CA1338702No1998-11-122013-11-12Canada
CA1335565No1995-05-162012-05-16Canada
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)229-231 °CPhysProp
water solubilitySolubleNot Available
logP1.27HANSCH,C ET AL. (1995)
Caco2 permeability-6.8ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility1.18 mg/mLALOGPS
logP1.41ALOGPS
logP0.92ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)9.53ChemAxon
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area206.07 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity134.59 m3·mol-1ChemAxon
Polarizability53.87 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8092
Blood Brain Barrier-0.9951
Caco-2 permeable-0.799
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9053
CYP450 2C9 substrateNon-substrate0.8042
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5888
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9209
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8911
Ames testAMES toxic0.9198
CarcinogenicityNon-carcinogens0.9534
BiodegradationNot ready biodegradable0.9672
Rat acute toxicity2.6644 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9752
hERG inhibition (predictor II)Non-inhibitor0.7195
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006t-0109000000-ac65f689e3fa439adddc

Taxonomy

Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthraquinones / Hexoses / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes
show 13 more
Substituents
Anthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinone, anthracycline antibiotic, aminoglycoside, deoxy hexoside, anthracycline (CHEBI:28748) / Other Polyketides, Anthracyclinones (C01661) / Anthracyclinones (LMPK13050001)

Targets

Kind
Nucleotide
Organism
Humans
Pharmacological action
Yes
Actions
Intercalation
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.
References
  1. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 Apr;45(4):649-56. [PubMed:8183243]
  2. Momparler RL, Karon M, Siegel SE, Avila F: Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976 Aug;36(8):2891-5. [PubMed:1277199]
  3. Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, Wang AH: Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990 Mar 13;29(10):2538-49. [PubMed:2334681]
Details
2. DNA topoisomerase 2-alpha
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28. [PubMed:17010609]
  3. Koehn H, Magan N, Isaacs RJ, Stowell KM: Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs. 2007 Apr;18(4):419-25. [PubMed:17351394]
  4. Hayashi S, Hatashita M, Matsumoto H, Shioura H, Kitai R, Kano E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int J Mol Med. 2006 Nov;18(5):909-15. [PubMed:17016621]
  5. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19. [PubMed:17578914]
  6. Menendez JA, Vellon L, Lupu R: DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec;18(6):1081-7. [PubMed:17089011]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Related to nucleologenesis, may play a role in the maintenance of the fundamental structure of the fibrillar center and dense fibrillar component in the nucleolus. It has intrinsic GTPase and ATPas...
Gene Name
NOLC1
Uniprot ID
Q14978
Uniprot Name
Nucleolar and coiled-body phosphoprotein 1
Molecular Weight
73602.49 Da
References
  1. Kim YK, Lee WK, Jin Y, Lee KJ, Jeon H, Yu YG: Doxorubicin binds to un-phosphorylated form of hNopp140 and reduces protein kinase CK2-dependent phosphorylation of hNopp140. J Biochem Mol Biol. 2006 Nov 30;39(6):774-81. [PubMed:17129415]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lu H, Chen CS, Waxman DJ: Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009 May;16(5):393-404. doi: 10.1038/cgt.2008.93. Epub 2008 Nov 14. [PubMed:19011599]
  2. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R: Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61. [PubMed:8452560]
  3. Diaz Flaque MC, Cayrol MF, Sterle HA, Del Rosario Aschero M, Diaz Albuja JA, Isse B, Farias RN, Cerchietti L, Rosemblit C, Cremaschi GA: Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells. Oncotarget. 2019 Apr 30;10(32):3051-3065. doi: 10.18632/oncotarget.26890. eCollection 2019 Apr 30. [PubMed:31105885]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Le Guellec C, Lacarelle B, Catalin J, Durand A: Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5. [PubMed:8258200]
  2. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Masek V, Anzenbacherova E, Etrych T, Strohalm J, Ulbrich K, Anzenbacher P: Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin. Drug Metab Dispos. 2011 Sep;39(9):1704-10. doi: 10.1124/dmd.110.037986. Epub 2011 Jun 3. [PubMed:21642392]
  2. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742]
  3. Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc) [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
Curator comments
There are limited data in the literature supporting the inhibitory actions of this drug on CYP1B1. The majority of the data suggests that it is an inducer of CYP1B1.
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Zordoky BN, El-Kadi AO: Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vascul Pharmacol. 2008 Oct-Dec;49(4-6):166-72. doi: 10.1016/j.vph.2008.07.004. Epub 2008 Jul 25. [PubMed:18707023]
  2. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41. [PubMed:11160641]
  3. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO: Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos. 2011 Aug;39(8):1440-50. doi: 10.1124/dmd.111.039123. Epub 2011 May 13. [PubMed:21571947]
  4. Grant MK, Seelig DM, Sharkey LC, Zordoky BN: Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. Biol Sex Differ. 2017 Jan 7;8:1. doi: 10.1186/s13293-016-0124-4. eCollection 2017. [PubMed:28078076]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-e2 9-reductase activity
Specific Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. ...
Gene Name
CBR1
Uniprot ID
P16152
Uniprot Name
Carbonyl reductase [NADPH] 1
Molecular Weight
30374.73 Da
References
  1. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, Klein K, Zanger UM, Maser E, Wojnowski L: Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20. doi: 10.1124/dmd.108.022251. Epub 2008 Jul 17. [PubMed:18635746]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Nadph binding
Specific Function
Has low NADPH-dependent oxidoreductase activity towards 4-benzoylpyridine and menadione (in vitro).
Gene Name
CBR3
Uniprot ID
O75828
Uniprot Name
Carbonyl reductase [NADPH] 3
Molecular Weight
30849.97 Da
References
  1. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW: Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63. doi: 10.1124/jpet.109.160614. Epub 2009 Dec 9. [PubMed:20007405]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
L-glucuronate reductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyd...
Gene Name
AKR1A1
Uniprot ID
P14550
Uniprot Name
Alcohol dehydrogenase [NADP(+)]
Molecular Weight
36572.71 Da
References
  1. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, Klein K, Zanger UM, Maser E, Wojnowski L: Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20. doi: 10.1124/dmd.108.022251. Epub 2008 Jul 17. [PubMed:18635746]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2....
Gene Name
AKR1C3
Uniprot ID
P42330
Uniprot Name
Aldo-keto reductase family 1 member C3
Molecular Weight
36852.89 Da
References
  1. Novotna R, Wsol V, Xiong G, Maser E: Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6. doi: 10.1016/j.toxlet.2008.06.858. Epub 2008 Jun 21. [PubMed:18616992]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Superoxide dismutase activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vit...
Gene Name
NQO1
Uniprot ID
P15559
Uniprot Name
NAD(P)H dehydrogenase [quinone] 1
Molecular Weight
30867.405 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675]
  2. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, Honma Y: Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol. 2000 Jul;58(1):27-36. [PubMed:10860924]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675]
  2. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, Honma Y: Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol. 2000 Jul;58(1):27-36. [PubMed:10860924]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. P...
Gene Name
NOS1
Uniprot ID
P29475
Uniprot Name
Nitric oxide synthase, brain
Molecular Weight
160969.095 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Ubiquitin protein ligase binding
Specific Function
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
Gene Name
NDUFS2
Uniprot ID
O75306
Uniprot Name
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial
Molecular Weight
52545.26 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Nadh dehydrogenase activity
Specific Function
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
Gene Name
NDUFS3
Uniprot ID
O75489
Uniprot Name
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial
Molecular Weight
30241.245 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Quinone binding
Specific Function
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
Gene Name
NDUFS7
Uniprot ID
O75251
Uniprot Name
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial
Molecular Weight
23563.3 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name
POR
Uniprot ID
P16435
Uniprot Name
NADPH--cytochrome P450 reductase
Molecular Weight
76689.12 Da
References
  1. Gutierrez PL, Gee MV, Bachur NR: Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75. [PubMed:6305277]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C, Drevs J: Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim). 2005 Oct;338(10):462-72. [PubMed:16211657]
  2. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F: Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007 May-Jun;18(3):702-16. Epub 2007 Mar 23. [PubMed:17378599]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997 May 15;246(1):186-92. [PubMed:9210482]
  2. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  3. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169]
  4. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272]
  5. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  7. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53. [PubMed:14499271]
  8. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6. [PubMed:1356264]
  9. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792]
  10. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. [PubMed:15211078]
  11. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
  12. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23. [PubMed:20179710]
  13. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. doi: 10.1007/s00280-009-0949-1. Epub 2009 Mar 3. [PubMed:19255759]
  14. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644]
  2. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726]
  3. Tribull TE, Bruner RH, Bain LJ: The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70. [PubMed:12765240]
  4. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490]
  5. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595]
  6. Wong IL, Chan KF, Tsang KH, Lam CY, Zhao Y, Chan TH, Chow LM: Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J Med Chem. 2009 Sep 10;52(17):5311-22. doi: 10.1021/jm900194w. [PubMed:19725578]
  7. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. doi: 10.1007/s00280-009-0949-1. Epub 2009 Mar 3. [PubMed:19255759]
  8. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW: Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172. doi: 10.1371/journal.pone.0005172. Epub 2009 Apr 23. [PubMed:19390592]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Cai J, Daoud R, Alqawi O, Georges E, Pelletier J, Gros P: Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry. 2002 Jun 25;41(25):8058-67. [PubMed:12069597]
  2. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043]
  2. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537]
  3. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380]
  4. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196]
  5. An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. [PubMed:19708828]
  6. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
  7. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821]
  8. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW: Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172. doi: 10.1371/journal.pone.0005172. Epub 2009 Apr 23. [PubMed:19390592]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic cation transmembrane transporter activity
Specific Function
High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is i...
Gene Name
SLC22A16
Uniprot ID
Q86VW1
Uniprot Name
Solute carrier family 22 member 16
Molecular Weight
64613.58 Da
References
  1. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23. [PubMed:20179710]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Not Available
Gene Name
ABCB8
Uniprot ID
Q9NUT2
Uniprot Name
ATP-binding cassette sub-family B member 8, mitochondrial
Molecular Weight
79988.17 Da
References
  1. Elliott AM, Al-Hajj MA: ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87. doi: 10.1158/1541-7786.MCR-08-0235. [PubMed:19147539]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transmembrane transporter activity
Specific Function
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the ma...
Gene Name
RALBP1
Uniprot ID
Q15311
Uniprot Name
RalA-binding protein 1
Molecular Weight
76062.86 Da
References
  1. Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S: Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25. [PubMed:17273774]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Folmer Y, Schneider M, Blum HE, Hafkemeyer P: Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007 Nov;14(11):875-84. Epub 2007 Aug 17. [PubMed:17704753]

Drug created on June 13, 2005 07:24 / Updated on April 04, 2020 08:56

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates